 |
471 Diseases |  |
207 Trials |
|
207 Trials |  |
10577 News |  |
| «12...117118119120121122123124125126127...132133» |
- || dactolisib (RTB101) / Adicet Bio
Trial primary completion date, Metastases: Efficacy and Safety of BEZ235 Compared to Everolimus in Patients With Advanced Pancreatic Neuroendocrine Tumors (clinicaltrials.gov) - Apr 20, 2014
P2, N=140, Recruiting, Sponsor: Novartis Pharmaceuticals
Trial primary completion date: Sep 2014 --> Jul 2014
- || dactolisib (RTB101) / Adicet Bio
Trial completion date, Metastases: Efficacy and Safety of BEZ235 Compared to Everolimus in Patients With Advanced Pancreatic Neuroendocrine Tumors (clinicaltrials.gov) - Apr 20, 2014
P2, N=140, Recruiting, Sponsor: Novartis Pharmaceuticals
Trial primary completion date: Sep 2014 --> Jul 2014 Trial completion date: Sep 2014 --> Jul 2014
- Halaven (eribulin mesylate) / Eisai
New P1 trial, Metastases: Eribulin Mesylate and Everolimus in Treating Patients With Triple-Negative Metastatic Breast Cancer (clinicaltrials.gov) - Apr 20, 2014
P1, N=45, Not yet recruiting, Sponsor: City of Hope Medical Center
- ||| everolimus / Generic mfg., sirolimus / Generic mfg.
Enrollment open, Adverse events, Combination therapy: Comparing Everolimus and Sirolimus in Renal Transplant Recipients (clinicaltrials.gov) - Apr 20, 2014
P=N/A, N=60, Recruiting, Sponsor: Dr.Ronald Pelletier
Trial completion date: Sep 2014 --> Jul 2014 Not yet recruiting --> Recruiting
- everolimus / Generic mfg.
Enrollment open, Combination therapy, Stroma: Mesenchymal Stromal Cell Therapy in Renal Recipients (clinicaltrials.gov) - Apr 14, 2014
P2, N=70, Recruiting, Sponsor: Leiden University Medical Center
Not yet recruiting --> Recruiting Not yet recruiting --> Recruiting
- |||||||||| everolimus / Generic mfg.
New P3 trial, Post-transplantation: REFLECT: REnal Function in Liver Transplantation: Everolimus With Calcineurin Inhibitor (CNI)-Sparing sTrategy (clinicaltrials.gov) - Apr 13, 2014
P3, N=415, Recruiting, Sponsor: Novartis Pharmaceuticals
- IO biomarker, Metastases: Analysis of Tumor Tissue and Circulating Genetic Material in the Blood to Obtain Further Insight in the Effectiveness of Everolimus When Combined With Exemestane (clinicaltrials.gov) - Apr 8, 2014
P=N/A, N=175, Recruiting, Sponsor: VU University Medical Center
- | everolimus / Generic mfg.
New P2 trial: EVINEC: Safety and Tolerability of Everolimus as Second-line Treatment in Poorly Differentiated Neuroendocrine Carcinoma / Neuroendocrine Carcinoma G3 (WHO 2010) and Neuroendocrine Tumor G3 - an Investigator Initiated Phase II Study (clinicaltrials.gov) - Apr 7, 2014
P2, N=40, Not yet recruiting, Sponsor: AIO-Studien-gGmbH
- ||| Erleada (apalutamide) / J&J
New P1 trial, Metastases: ARN 509 Plus Everolimus in Men With Progressive Metastatic Castration-Resistant Prostate Cancer After Treatment With Abiraterone Acetate (clinicaltrials.gov) - Apr 6, 2014
P1, N=58, Recruiting, Sponsor: Memorial Sloan-Kettering Cancer Center
- everolimus / Generic mfg., paclitaxel / Generic mfg.
Trial completion: CROSS: Choice Of Optimal Strategy For Bifurcation Lesions With Normal Side Branch (clinicaltrials.gov) - Apr 5, 2014
P4, N=600, Completed, Sponsor: Seung-Jung Park
Not yet recruiting --> Recruiting Active, not recruiting --> Completed
- ||| Roferon A (recombinant interferon alfa-2a) / Roche, Avastin (bevacizumab) / Roche
Enrollment change, Metastases: Safety and Efficacy of Bevacizumab Plus RAD001 Versus Interferon Alfa-2a and Bevacizumab for the First-line Treatment in Adult Patients With Kidney Cancer (clinicaltrials.gov) - Apr 3, 2014
P2, N=467, Completed, Sponsor: Novartis Pharmaceuticals
Active, not recruiting --> Completed N=364 --> 467
- ||| Verzenio (abemaciclib) / Eli Lilly
Enrollment open, Combination therapy, Metastases: A Study of LY2835219 (Abemaciclib) in Combination With Therapies for Breast Cancer That Has Spread (clinicaltrials.gov) - Apr 3, 2014
P1, N=81, Recruiting, Sponsor: Eli Lilly and Company
N=364 --> 467 Not yet recruiting --> Recruiting
- ||| Erleada (apalutamide) / J&J
Enrollment open, Metastases: ARN 509 Plus Everolimus in Men With Progressive Metastatic Castration-Resistant Prostate Cancer After Treatment With Abiraterone Acetate (clinicaltrials.gov) - Apr 2, 2014
P1, N=58, Recruiting, Sponsor: Memorial Sloan-Kettering Cancer Center
Not yet recruiting --> Recruiting Not yet recruiting --> Recruiting
- imatinib / Generic mfg., everolimus / Generic mfg.
Enrollment change, Combination therapy, Metastases: Everolimus in Combination With Imatinib Mesylate in Treating Patients With Locally Advanced, Locally Recurrent, or Metastatic Soft Tissue Sarcoma (clinicaltrials.gov) - Mar 31, 2014
P1/2, N=14, Completed, Sponsor: National Cancer Institute (NCI)
Not yet recruiting --> Recruiting N=33 --> 14
- | Farydak (panobinostat) / Secura Bio
Enrollment change: Panobinostat (LBH589) Plus Everolimus (RAD001) in Patients With Relapsed and Refractory Lymphoma (clinicaltrials.gov) - Mar 31, 2014
P1/2, N=31, Completed, Sponsor: M.D. Anderson Cancer Center
N=33 --> 14 N=60 --> 31
- ||||| Opdivo (nivolumab) / BMS
Enrollment closed, PD(L)-1 Biomarker, IO biomarker, Metastases: Study of Nivolumab (BMS-936558) vs. Everolimus in Pre-Treated Advanced or Metastatic Clear-cell Renal Cell Carcinoma (CheckMate 025) (clinicaltrials.gov) - Mar 31, 2014
P3, N=822, Active, not recruiting, Sponsor: Bristol-Myers Squibb
N=60 --> 31 Recruiting --> Active, not recruiting
- imatinib / Generic mfg., everolimus / Generic mfg.
Trial completion, Combination therapy, Metastases: Everolimus in Combination With Imatinib Mesylate in Treating Patients With Locally Advanced, Locally Recurrent, or Metastatic Soft Tissue Sarcoma (clinicaltrials.gov) - Mar 31, 2014
P1/2, N=14, Completed, Sponsor: National Cancer Institute (NCI)
Recruiting --> Active, not recruiting Active, not recruiting --> Completed
- | Farydak (panobinostat) / Secura Bio
Trial completion: Panobinostat (LBH589) Plus Everolimus (RAD001) in Patients With Relapsed and Refractory Lymphoma (clinicaltrials.gov) - Mar 31, 2014
P1/2, N=31, Completed, Sponsor: M.D. Anderson Cancer Center
Active, not recruiting --> Completed Active, not recruiting --> Completed
- ||| retaspimycin (IPI-504) / Infinity Pharma
Enrollment closed, Combination therapy: Phase 1b/2 Study of Retaspimycin HCl (IPI-504) in Combination With Everolimus in KRAS Mutant Non-small Cell Lung Cancer (clinicaltrials.gov) - Mar 30, 2014
P1/2, N=70, Active, not recruiting, Sponsor: Infinity Pharmaceuticals, Inc.
Active, not recruiting --> Completed Recruiting --> Active, not recruiting
- Inlyta (axitinib) / Pfizer
Enrollment closed, Metastases: EVAX: Study of the Combination of Axitinib Plus Everolimus in Patients With Malignant Advanced Solid Tumors (clinicaltrials.gov) - Mar 30, 2014
P1, N=25, Active, not recruiting, Sponsor: University Hospital, Bordeaux
Recruiting --> Active, not recruiting Recruiting --> Active, not recruiting
- everolimus / Generic mfg.
Enrollment closed, Metastases: Everolimus and Pasireotide (SOM230) in Patients With Advanced or Metastatic Hepatocellular Carcinoma (clinicaltrials.gov) - Mar 26, 2014
P2, N=30, Active, not recruiting, Sponsor: UNC Lineberger Comprehensive Cancer Center
Recruiting --> Active, not recruiting Recruiting --> Active, not recruiting
- everolimus / Generic mfg.
Enrollment closed, Metastases: RAD001 in Advanced Gastric Cancer Who Failed Standard First-line Treatment With pS6 Ser 240/4 Expression (clinicaltrials.gov) - Mar 26, 2014
P2, N=45, Active, not recruiting, Sponsor: Asan Medical Center
Recruiting --> Active, not recruiting Recruiting --> Active, not recruiting
- ||||| everolimus / Generic mfg.
New P4 trial: Novartis Everolimus Transition (clinicaltrials.gov) - Mar 24, 2014
P4, N=60, Recruiting, Sponsor: Medical University of South Carolina
- | Avastin (bevacizumab) / Roche
Enrollment closed, Metastases: Safety Study & Effectiveness of Docetaxel With RAD001 and Bevacizumab in Men With Advanced Prostate Cancer (clinicaltrials.gov) - Mar 24, 2014
P1/2, N=42, Active, not recruiting, Sponsor: University of Southern California
Recruiting --> Active, not recruiting Recruiting --> Active, not recruiting
- simvastatin / Generic mfg.
Enrollment open: Safety of Simvastatin in LAM and TSC (clinicaltrials.gov) - Mar 23, 2014
P1/2, N=10, Recruiting, Sponsor: University of Pennsylvania
Recruiting --> Active, not recruiting Not yet recruiting --> Recruiting
- |||| everolimus / Generic mfg.
Enrollment open: Novartis Everolimus Transition (clinicaltrials.gov) - Mar 20, 2014
P4, N=60, Recruiting, Sponsor: Medical University of South Carolina
Not yet recruiting --> Recruiting Not yet recruiting --> Recruiting
- cixutumumab (IMC A12) / Eli Lilly
Enrollment change, Metastases: Cixutumumab, Everolimus, and Octreotide Acetate in Treating Patients With Advanced Low to Intermediate Grade Neuroendocrine Carcinoma (clinicaltrials.gov) - Mar 19, 2014
P1, N=19, Active, not recruiting, Sponsor: National Cancer Institute (NCI)
Not yet recruiting --> Recruiting N=48 --> 19
- everolimus / Generic mfg.
Enrollment closed: AML1208: Everolimus MICE-regimen in Treating Older Patients With Newly Diagnosed Acute Myeloid Leukemia (clinicaltrials.gov) - Mar 19, 2014
P1, N=18, Active, not recruiting, Sponsor: Gruppo Italiano Malattie EMatologiche dell'Adulto
N=48 --> 19 Recruiting --> Active, not recruiting
- everolimus / Generic mfg.
IO biomarker: MicroRNA Expression in Everolimus-based Versus Tacrolimus-based Regimens in Kidney Transplantation (clinicaltrials.gov) - Mar 17, 2014
P=N/A, N=50, Recruiting, Sponsor: Chulalongkorn University
- | everolimus / Generic mfg.
Enrollment change, Metastases: RAD001 in Advanced Hepatocellular Carcinoma (clinicaltrials.gov) - Mar 15, 2014
P1/2, N=28, Completed, Sponsor: Massachusetts General Hospital
Recruiting --> Active, not recruiting N=40 --> 28
- | everolimus / Generic mfg.
Trial completion, Metastases: RAD001 in Advanced Hepatocellular Carcinoma (clinicaltrials.gov) - Mar 15, 2014
P1/2, N=28, Completed, Sponsor: Massachusetts General Hospital
N=40 --> 28 Recruiting --> Completed
- | Archexin (WGI-0201) - Zhejiang Haichang Bio / Tech
New P1/2 trial, Combination therapy, Metastases: Dose-Finding, Safety and Efficacy Study of RX-0201 Plus Everolimus in Metastatic Renal Cell Cancer (clinicaltrials.gov) - Mar 13, 2014
P1/2, N=39, Not yet recruiting, Sponsor: Rexahn Pharmaceuticals, Inc.
- everolimus / Generic mfg.
Enrollment change, IO biomarker: Trial of RAD001 in Patients With Operable Non-Small Cell Lung Cancer (NSCLC) (clinicaltrials.gov) - Mar 13, 2014
P2, N=53, Completed, Sponsor: Emory University
Recruiting --> Completed N=35 --> 53
- everolimus / Generic mfg.
Trial completion, IO biomarker: Trial of RAD001 in Patients With Operable Non-Small Cell Lung Cancer (NSCLC) (clinicaltrials.gov) - Mar 13, 2014
P2, N=53, Completed, Sponsor: Emory University
N=35 --> 53 Recruiting --> Completed
- |||||| Herceptin (trastuzumab) / Roche
Enrollment open, Combination therapy, Metastases: BOLERO-1: Everolimus in Combination With Trastuzumab and Paclitaxel in the Treatment of HER2 Positive Locally Advanced or Metastatic Breast Cancer (clinicaltrials.gov) - Mar 12, 2014
P3, N=719, Recruiting, Sponsor: Novartis Pharmaceuticals
Recruiting --> Completed Active, not recruiting --> Recruiting
- ||||| Thymoglobulin (anti-thymocyte globulin (rabbit)) / Sanofi
Clinical: Everolimus + Very Low Tacrolimus vs Enteric-coated Mycophenolate Sodium + Low Tacrolimus in de Novo Renal Transplant (clinicaltrials.gov) - Mar 10, 2014
P4, N=120, Recruiting, Sponsor: Ronaldo de Matos Esmeraldo, MD
- | carboplatin / Generic mfg., everolimus / Generic mfg.
Trial completion, Metastases: RAD001 Plus Carboplatin in Breast Cancer Patients (clinicaltrials.gov) - Mar 10, 2014
P2, N=25, Completed, Sponsor: New York University School of Medicine
Active, not recruiting --> Recruiting Active, not recruiting --> Completed
- everolimus / Generic mfg., sorafenib / Generic mfg.
Enrollment closed: SERIO: Phase II Open Label, Non-randomized Study of Sorafenib and Everolimus in Relapsed and Non-resectable Osteosarcoma (clinicaltrials.gov) - Mar 9, 2014
P2, N=37, Active, not recruiting, Sponsor: Italian Sarcoma Group
Active, not recruiting --> Completed Recruiting --> Active, not recruiting
- | everolimus / Generic mfg.
New P4 trial: Safety and Efficacy of Everolimus Treatment in Liver Transplantation for Liver Cancer (clinicaltrials.gov) - Mar 5, 2014
P4, N=336, Recruiting, Sponsor: Baylor Research Institute
- |||| everolimus / Generic mfg.
Trial completion: SCHEDULE - Scandinavian Heart Transplant Everolimus de Novo Study With Early Calcineurin Inhibitor (CNI) Avoidance (clinicaltrials.gov) - Mar 5, 2014
P4, N=100, Completed, Sponsor: Novartis Pharmaceuticals
Recruiting --> Active, not recruiting Recruiting --> Completed
- ||||||| everolimus / Generic mfg.
Trial completion: EVERHEART: Everolimus in de Novo Heart Transplant Recipients (clinicaltrials.gov) - Mar 5, 2014
P3, N=200, Completed, Sponsor: Novartis
Recruiting --> Completed Recruiting --> Completed
- || everolimus / Generic mfg., cyclosporine / Generic mfg.
Trial completion: Feasibility and Safety of Early Switch to Everolimus From Cyclosporine in de Novo Renal Transplant Patients (clinicaltrials.gov) - Mar 5, 2014
P3, N=20, Completed, Sponsor: Novartis Pharmaceuticals
Recruiting --> Completed Active, not recruiting --> Completed
- |||| Trial completion: Efficacy, Safety and Tolerability of Everolimus in Preventing End-stage Renal Disease in Patients With Autosomal Dominant Polycystic Kidney Disease (clinicaltrials.gov) - Mar 5, 2014
P4, N=431, Completed, Sponsor: Novartis Pharmaceuticals
Active, not recruiting --> Completed Active, not recruiting --> Completed
- ||||||| Trial completion: Comparison of CNI-based Regimen Versus CNI-free Regimen in Kidney Transplant Recipients. (clinicaltrials.gov) - Mar 5, 2014
P3, N=300, Completed, Sponsor: Novartis Pharmaceuticals
Active, not recruiting --> Completed Recruiting --> Completed
- ||| Herceptin (trastuzumab) / Roche
Trial completion, Combination therapy, Metastases: Efficacy and Safety of Everolimus in Combination Therapy, in Patients With HER2-overexpressing Metastatic Breast Cancer (clinicaltrials.gov) - Mar 5, 2014
P1, N=134, Completed, Sponsor: Novartis Pharmaceuticals
Recruiting --> Completed Active, not recruiting --> Completed
- | Simulect (basiliximab) / Novartis
Trial completion, Combination therapy: Efficacy and Safety of Everolimus+EC-MPS After Early CNI Elimination vs EC-MPS +Tacrolimus in Renal Transplant Recipients (clinicaltrials.gov) - Mar 4, 2014
P4, N=40, Completed, Sponsor: Novartis
Active, not recruiting --> Completed Recruiting --> Completed
- ||| lenalidomide / Generic mfg., everolimus / Generic mfg.
Enrollment closed, Combination therapy: Everolimus and Lenalidomide in Treating Patients With Relapsed or Refractory Non-Hodgkin or Hodgkin Lymphoma (clinicaltrials.gov) - Mar 4, 2014
P1/2, N=59, Active, not recruiting, Sponsor: Mayo Clinic
Recruiting --> Completed Recruiting --> Active, not recruiting
- ||||| everolimus / Generic mfg.
Trial initiation date, Combination therapy: 4EVERLUNG: Efficacy Regarding Renal Function of Everolimus in Combination With Specific Standard Immunosuppressive Regimen Lung Transplant Recipients (clinicaltrials.gov) - Mar 3, 2014
P3, N=232, Recruiting, Sponsor: Novartis Pharmaceuticals
Recruiting --> Active, not recruiting Initiation date: Sep 2011 --> Feb 2012
- ||||| everolimus / Generic mfg.
Enrollment change, Combination therapy: 4EVERLUNG: Efficacy Regarding Renal Function of Everolimus in Combination With Specific Standard Immunosuppressive Regimen Lung Transplant Recipients (clinicaltrials.gov) - Mar 3, 2014
P3, N=232, Recruiting, Sponsor: Novartis Pharmaceuticals
Initiation date: Sep 2011 --> Feb 2012 N=300 --> 232
- ||||| everolimus / Generic mfg.
Enrollment closed, Combination therapy: HEPHAISTOS: Efficacy of Everolimus in Combination With Tacrolimus in Liver Transplant Recipients (clinicaltrials.gov) - Mar 3, 2014
P3, N=330, Active, not recruiting, Sponsor: Novartis Pharmaceuticals
N=300 --> 232 Recruiting --> Active, not recruiting